Svennilson Peter's Form 4 filing
Tenaya Therapeutics, Inc. (TNYA) · filed Feb 26, 2026
- Accession no.
- 0001193125-26-076814
- Filed
- Feb 26, 2026, 4:23 PM ET
- Trade date
- Feb 24-25, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $2.38M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Svennilson PeterCIK 0001606074 | 10% Owner |
| Kutzkey TimCIK 0001614186 | 10% Owner |
| Column Group III-A, LPCIK 0001668085 | 10% Owner |
| Column Group III, LPCIK 0001668159 | 10% Owner |
| Column Group III GP, LPCIK 0001790965 | 10% Owner |
| Column Group Opportunity III, LPCIK 0001931825 | 10% Owner |
| TCG Opportunity III GP, LLCCIK 0001932445 | 10% Owner |
| Column Group Opportunity III GP, LPCIK 0001932874 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Common Stock | SSaleDisposed | −309,228 | $0.6153F1 | −$190,267.99 | 1,649,281 | Indirect | |
| Feb 24, 2026 | Common Stock | SSaleDisposed | −349,212 | $0.6153F1 | −$214,870.14 | 1,862,545 | Indirect | |
| Feb 25, 2026 | Common Stock | SSaleDisposed | −1,649,281 | $0.5624F4 | −$927,555.63 | 0 | Indirect | |
| Feb 25, 2026 | Common Stock | SSaleDisposed | −1,862,545 | $0.5624F4 | −$1,047,495.31 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.584 to $0.6392, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.55 to $0.641, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 2 transactions in Table I.